文献速递心脑血管急症重症综合管理与镇静镇痛

院外心脏骤停与支架血栓:轻度治疗性低温下直接PCI患者替格瑞洛与氯吡格雷的比较

Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia.
PubMed 文献 · Resuscitation · 2017-02-24
一句话结论在院外心脏骤停后接受轻度治疗性低温及直接PCI的急性冠脉综合征患者中,替格瑞洛较氯吡格雷与更低的支架血栓发生率相关,出血事件无差异。

该研究纳入2010年1月至2016年8月间144例院外心脏骤停后接受轻度治疗性低温的患者,其中114例(79%)为急性冠脉综合征,98例(67.3%)接受直接PCI并植入支架。在98例中,61例(62.2%)使用氯吡格雷,32例(32.6%)使用替格瑞洛。住院期间,氯吡格雷组 probable/definite 支架血栓发生率显著高于替格瑞洛组(11.4% vs 0%,p=0.04),任何出血(28.6% vs 25%,p=0.645)及重大出血(BARC 3或5)(11.4% vs 12.5%,p=0.685)无显著差异,院内死亡率无差异(26.2% vs 25%,p=0.862)。作者认为,在此类患者中替格瑞洛可能是氯吡格雷的有效替代。

要点

  • 在院外心脏骤停后接受轻度治疗性低温及直接PCI的急性冠脉综合征患者中,氯吡格雷组 probable/definite 支架血栓发生率为11.4%,替格瑞洛组为0%(p=0.04)。
  • 两组任何出血发生率无显著差异(氯吡格雷28.6% vs 替格瑞洛25%,p=0.645)。
  • 两组重大出血(BARC 3或5)发生率无显著差异(氯吡格雷11.4% vs 替格瑞洛12.5%,p=0.685)。
  • 两组院内死亡率无显著差异(氯吡格雷26.2% vs 替格瑞洛25%,p=0.862)。
  • 作者认为,替格瑞洛可能是此类患者中氯吡格雷的有效替代。

适用人群与场景

  • 院外心脏骤停后接受轻度治疗性低温的昏迷幸存者,且为急性冠脉综合征并接受直接PCI及支架植入的患者。

研究设计与关键结果

  • 研究类型为比较替格瑞洛与氯吡格雷的观察性研究,纳入2010年1月至2016年8月共144例院外心脏骤停后接受轻度治疗性低温的患者。
  • 144例中114例(79%)为急性冠脉综合征,98例(67.3%)接受直接PCI并植入支架;其中61例(62.2%)使用氯吡格雷,32例(32.6%)使用替格瑞洛。
  • 住院期间 probable/definite 支架血栓发生率:氯吡格雷组11.4% vs 替格瑞洛组0%(p=0.04)。
  • 任何出血发生率:氯吡格雷组28.6% vs 替格瑞洛组25%(p=0.645),无显著差异。
  • 重大出血(BARC 3或5)发生率:氯吡格雷组11.4% vs 替格瑞洛组12.5%(p=0.685),无显著差异。
  • 院内死亡率:氯吡格雷组26.2% vs 替格瑞洛组25%(p=0.862),无显著差异。

证据类型、等级与局限

  • 证据类型:观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与其他场景类似,替格瑞洛可能是院外心脏骤停后接受轻度治疗性低温及直接PCI的急性冠脉综合征患者中氯吡格雷的有效替代。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Out-of-Hospital Cardiac Arrest (OHCA) and mild therapeutic hypothermia (MTH) have been linked to increased risk of Stent Thrombosis (ST) in comatose survivors who undergo percutaneous coronary intervention (PCI). In this sense, there is no formal recommendation about which antiplatelet regimen should be used in patients with acute coronary syndromes (ACS) after OHCA.

AIMS: To compare the incidence of probable/definite ST and bleeding events between ticagrelor and clopidogrel, in patients with ACS under MTH after an OHCA.

METHODS AND RESULTS: From January 2010 to August 2016, 144 patients underwent MTH after an OHCA. Overall, 114 had an ACS (79%) and 98 (67,3%) were treated with primary PCI and stent implantation. Among them, 61 (62,2%) were treated with clopidogrel, and 32 (32,6%) with ticagrelor. During hospitalization, the incidence of probable or definite ST was significantly higher in patients receiving clopidogrel compared to ticagrelor (11,4% vs. 0%; p: 0.04), and no significant differences in any (28,6% vs. 25%; p: 0.645) or major bleeding (BARC 3 or 5) (11,4% vs. 12,5%; p: 0.685) were found. Hospital mortality did not differ between groups (26,2% vs. 25%; p: 0.862).

CONCLUSIONS: In this study, as compared to clopidogrel, ticagrelor was associated with a lower rate of ST, without differences in haemorrhagic events in patients with OHCA for an ACS under MTH. Similarly to other settings, ticagrelor might be a valid alternative to clopidogrel in these patients.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Jiménez-Brítez G, Freixa X, Flores-Umanzor E, et al. Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia. Resuscitation. 2017. PMID: 28242212. doi:10.1016/j.resuscitation.2017.02.015

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。